Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,619 across all filing types
Latest filing 2020-06-05 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
第八届董事局第八次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement from Shenzhen Haier Bioengineering Co., Ltd. regarding the resolutions passed at the 8th meeting of the 8th Board of Directors. It includes details about the appointment of two new vice presidents, changes in the company's securities affairs representative, approval of senior management remuneration standards, and the decision to convene the 2019 Annual General Meeting. The document contains no financial statements or detailed financial data but focuses on board and senior management changes and related corporate governance matters. Therefore, it fits the category of Board/Management Information (MANG). The document length is short (1585 characters), and it is not an announcement of a report publication but a substantive announcement of board decisions.
2020-06-05 Chinese
关于公司证券事务代表变更的公告
Board/Management Information Classification · 100% confidence The document is a company announcement regarding the change of the company's securities affairs representative. It details the resignation of the previous representative and the appointment of a new one, including the new representative's biography and contact information. There is no financial data, report, or regulatory filing referenced beyond this personnel change. This fits the category of Board/Management Information (MANG), which covers announcements of changes in senior management or board members.
2020-06-05 Chinese
关于召开2019年年度股东大会通知的公告
AGM Information Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2019 Annual General Meeting (AGM) of Shenzhen Haier Bioengineering Co., Ltd. It includes information about the meeting date, voting procedures, agenda items including the 2019 annual report, financial statements, profit distribution plan, and other proposals to be voted on. The document also contains instructions for registration, proxy voting, and contact details. It does not contain the actual annual report or financial statements but rather serves as a notice to shareholders about the AGM and the matters to be discussed and voted upon. The document length is 4221 characters, which is relatively short and consistent with an AGM notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2020-06-05 Chinese
关于股东部分股份解押及质押的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the partial release and new pledging of shares by a major shareholder (the controlling shareholder) of the company. It details the number of shares pledged and released, the pledgee institutions, and the purpose of the pledges (financing credit enhancement). It also provides background information on the controlling shareholder and confirms no risks or violations related to the pledges. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory announcement about share pledging activities by a major shareholder, which fits the category of Major Shareholding Notification (MRQ). The document length is about 3209 characters, and it is not a report or a certification but a disclosure of share pledge changes by a major shareholder.
2020-05-26 Chinese
关于公司非公开发行股票申请文件二次反馈意见的回复
Capital/Financing Update Classification · 95% confidence The document is a detailed response to a regulatory authority (China Securities Regulatory Commission) regarding a non-public stock issuance application. It includes extensive financial and operational data, asset structure analysis, R&D investment details, and comparisons with industry peers. The content is focused on compliance, financial metrics, and regulatory feedback responses related to a capital raising activity. This aligns with a Capital/Financing Update (CAP) filing, as it pertains to the company's fundraising and capital structure changes. The document is lengthy (15,000 characters) and contains substantive financial and operational data, not merely an announcement or certification. Therefore, it is classified as a Capital/Financing Update (CAP).
2020-05-18 Chinese
非公开发行股票申请文件二次反馈意见回复的公告
Capital/Financing Update Classification · 90% confidence The document is a public announcement by Shenzhen Haiwang Bioengineering Co., Ltd. regarding their response to the second round of feedback from the China Securities Regulatory Commission (CSRC) on their non-public stock issuance application. It mentions the submission of written feedback and supplementary materials as required by the regulatory authority. The document is short (828 characters) and primarily serves as a disclosure of the company's compliance and ongoing regulatory process. It does not contain financial statements, detailed financial data, or the actual application documents themselves. Therefore, it is an announcement related to capital raising activities but not the actual financing update report. Given the nature of the document as a regulatory feedback response announcement related to a capital raising process, the most appropriate classification is Capital/Financing Update (CAP).
2020-05-18 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.